Brokerages Set Strongbridge Biopharma plc (NASDAQ:SBBP) PT at $14.67
Strongbridge Biopharma plc (NASDAQ:SBBP) has been assigned an average rating of “Buy” from the ten research firms that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $13.07.
Several brokerages have issued reports on SBBP. Zacks Investment Research cut Strongbridge Biopharma from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. TheStreet cut Strongbridge Biopharma from a “c-” rating to a “d+” rating in a report on Wednesday, May 15th. BidaskClub upgraded Strongbridge Biopharma from a “strong sell” rating to a “sell” rating in a report on Friday, April 26th. Finally, ValuEngine cut Strongbridge Biopharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, May 1st.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. D. E. Shaw & Co. Inc. grew its holdings in shares of Strongbridge Biopharma by 89.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 355,874 shares of the biotechnology company’s stock worth $1,594,000 after purchasing an additional 168,243 shares during the period. Hudson Bay Capital Management LP lifted its stake in Strongbridge Biopharma by 48.1% during the 4th quarter. Hudson Bay Capital Management LP now owns 1,000,000 shares of the biotechnology company’s stock worth $4,480,000 after acquiring an additional 324,900 shares in the last quarter. 683 Capital Management LLC lifted its stake in Strongbridge Biopharma by 183.2% during the 4th quarter. 683 Capital Management LLC now owns 848,700 shares of the biotechnology company’s stock worth $3,802,000 after acquiring an additional 549,000 shares in the last quarter. Private Advisors LLC acquired a new position in Strongbridge Biopharma during the 1st quarter worth about $263,000. Finally, Stifel Financial Corp acquired a new position in Strongbridge Biopharma during the 4th quarter worth about $73,000. Institutional investors and hedge funds own 50.12% of the company’s stock.
Strongbridge Biopharma (NASDAQ:SBBP) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.09. The company had revenue of $4.34 million during the quarter, compared to analysts’ expectations of $4.69 million. Strongbridge Biopharma had a return on equity of 79.31% and a net margin of 227.79%. Sell-side analysts expect that Strongbridge Biopharma will post -1.36 earnings per share for the current year.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.
Read More: Why Invest in Dividend Achievers?
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.